J.P. Morgan is out with its report today on Merck & Co. MRK, raising its PT from $42 to $44.
In a note to clients, J.P. Morgan writes, "We are increasing our MRK sales and EPS estimates following strong 1Q/11 results. Our new estimates are toward the
high end of the company's 2011 guidance range. We are raising our PT by $2 to $44.
J.P. Morgan maintains Overweight on MRK.
Shares of MRK closed Friday at $35.95, up 0.50% from Thursday's close.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in